These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30880775)

  • 1. Role of stereotactic body radiation therapy in liver metastasis: A pilot study from tertiary cancer institute in India.
    Kumar S; Kapoor R; Oinam AS; Kalra N; Duseja A
    J Cancer Res Ther; 2019; 15(1):169-175. PubMed ID: 30880775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome and toxicity of radiotherapy for inferior vena cava tumor thrombus in HCC patients: A retrospective study.
    Lee SJ; Jang HS; Choi YK
    Medicine (Baltimore); 2021 Jun; 100(25):e26390. PubMed ID: 34160420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.
    Scorsetti M; Arcangeli S; Tozzi A; Comito T; Alongi F; Navarria P; Mancosu P; Reggiori G; Fogliata A; Torzilli G; Tomatis S; Cozzi L
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):336-42. PubMed ID: 23433800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
    Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
    Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.
    Lasley FD; Mannina EM; Johnson CS; Perkins SM; Althouse S; Maluccio M; Kwo P; Cárdenes H
    Pract Radiat Oncol; 2015; 5(5):e443-e449. PubMed ID: 25899219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?
    Vautravers-Dewas C; Dewas S; Bonodeau F; Adenis A; Lacornerie T; Penel N; Lartigau E; Mirabel X
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e39-47. PubMed ID: 21377292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single institution experience treating adrenal metastases with stereotactic body radiation therapy.
    Shah MM; Isrow D; Fareed MM; Wen N; Ryu S; Ajlouni M; Siddiqui F
    J Cancer Res Ther; 2019 Mar; 15(Supplement):S27-S32. PubMed ID: 30900616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
    Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
    Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of dosimetric variations of liver radiotherapy using deformable registration of planning CT and cone-beam CT.
    Huang P; Yu G; Chen J; Ma C; Qin S; Yin Y; Liang Y; Li H; Li D
    J Appl Clin Med Phys; 2017 Jan; 18(1):66-75. PubMed ID: 28291931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
    Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
    J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases.
    Folkert MR; Meyer JJ; Aguilera TA; Yokoo T; Sanford NN; Rule WG; Mansour J; Yopp A; Polanco P; Hannan R; Nedzi LA; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1387-1395. PubMed ID: 33340601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study.
    Guckenberger M; Sweeney RA; Hawkins M; Belderbos J; Andratschke N; Ahmed M; Madani I; Mantel F; Steigerwald S; Flentje M
    Cancer; 2018 May; 124(9):2001-2009. PubMed ID: 29499073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
    Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
    Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance of hypofractionated stereotactic radiotherapy for hepatic tumours].
    Le Bon M; Lapeyre M; Moreau J; Bellière-Calandry A; Pezet D; Abergel A; Bellini R; Kwiatkowski F; Verrelle P; Martin F; Benoît C
    Cancer Radiother; 2019 Sep; 23(5):385-394. PubMed ID: 31300328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.
    Alsuhaibani A; Elashwah A; Alkafi A; Constantinescus C; ALzorkany F
    J Gastrointest Cancer; 2019 Dec; 50(4):879-887. PubMed ID: 30291546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
    Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
    Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.